Personalized Medicine

Oral Toxicities Associated with Cancer Therapies: What’s Old Is New Again

Meg Barbor, MPH

October 2018, Vol 9, No 3 - Cancer Drugs

Vienna, Austria—New cancer therapies have significantly improved survival outcomes, but have brought with them a wide range of oral toxicities, many of which are class-specific and otherwise new to the field of oncology, according to Nathaniel S. Treister, DMD, DMSc, Division Chief, Division of Oral Medicine and Dentistry, Brigham and Women’s Hospital, Boston, MA. [ Read More ]

TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition

Phoebe Starr

October 2018, Vol 9, No 3 - Emerging Therapies

Chicago, IL—A novel approach using the investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Keytruda) may have the potential to reverse resistance to anti–PD-1 therapy, according to data from a pre­liminary phase 1b clinical trial. The addition of CMP-001 to pembrolizu­mab was well-tolerated, with encouraging antitumor responses in patients with metastatic melanoma that progressed with or after treatment with a PD-1 inhibitor. [ Read More ]

Two New Therapies Active in NSCLC with EGFR/HER2 Exon 20 Mutations

Phoebe Starr

October 2018, Vol 9, No 3 - Emerging Therapies

Toronto, Canada—Researchers are chipping away at the genetic subtypes of non–small-cell lung cancer (NSCLC). At the recent International Association for the Study of Lung Cancer World Conference, attention was focused on new drugs for NSCLC associated with EGFR and HER2 exon 20 insertions or mutations, which account for anywhere from 3% to 7% of all cases of NSCLC. The presence of these genetic alterations is associated with primary resistance to tyrosine kinase inhibitors (TKIs), with response rates below 12%. [ Read More ]